AU2016333982A1 - Method of treating medulloblastoma with an EZH2 inhibitor - Google Patents

Method of treating medulloblastoma with an EZH2 inhibitor Download PDF

Info

Publication number
AU2016333982A1
AU2016333982A1 AU2016333982A AU2016333982A AU2016333982A1 AU 2016333982 A1 AU2016333982 A1 AU 2016333982A1 AU 2016333982 A AU2016333982 A AU 2016333982A AU 2016333982 A AU2016333982 A AU 2016333982A AU 2016333982 A1 AU2016333982 A1 AU 2016333982A1
Authority
AU
Australia
Prior art keywords
pct
rule
substitute sheet
ezh2
ezh2 inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2016333982A
Other languages
English (en)
Inventor
Heike KEILHACK
Rajeev Vibhakar
Nigel J. WATERS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epizyme Inc
University of Colorado Colorado Springs
Original Assignee
Epizyme Inc
University of Colorado System
University of Colorado Colorado Springs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epizyme Inc, University of Colorado System, University of Colorado Colorado Springs filed Critical Epizyme Inc
Publication of AU2016333982A1 publication Critical patent/AU2016333982A1/en
Priority to AU2021204331A priority Critical patent/AU2021204331A1/en
Priority to AU2023246384A priority patent/AU2023246384A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
AU2016333982A 2015-10-06 2016-10-05 Method of treating medulloblastoma with an EZH2 inhibitor Abandoned AU2016333982A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2021204331A AU2021204331A1 (en) 2015-10-06 2021-06-25 Method of treating medulloblastoma with an ezh2 inhibitor
AU2023246384A AU2023246384A1 (en) 2015-10-06 2023-10-09 Method of treating medulloblastoma with an ezh2 inhibitor

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562238074P 2015-10-06 2015-10-06
US62/238,074 2015-10-06
US201662299312P 2016-02-24 2016-02-24
US62/299,312 2016-02-24
PCT/US2016/055554 WO2017062495A2 (en) 2015-10-06 2016-10-05 Method of treating medulloblastoma with an ezh2 inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021204331A Division AU2021204331A1 (en) 2015-10-06 2021-06-25 Method of treating medulloblastoma with an ezh2 inhibitor

Publications (1)

Publication Number Publication Date
AU2016333982A1 true AU2016333982A1 (en) 2018-04-26

Family

ID=58488487

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2016333982A Abandoned AU2016333982A1 (en) 2015-10-06 2016-10-05 Method of treating medulloblastoma with an EZH2 inhibitor
AU2021204331A Abandoned AU2021204331A1 (en) 2015-10-06 2021-06-25 Method of treating medulloblastoma with an ezh2 inhibitor
AU2023246384A Abandoned AU2023246384A1 (en) 2015-10-06 2023-10-09 Method of treating medulloblastoma with an ezh2 inhibitor

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2021204331A Abandoned AU2021204331A1 (en) 2015-10-06 2021-06-25 Method of treating medulloblastoma with an ezh2 inhibitor
AU2023246384A Abandoned AU2023246384A1 (en) 2015-10-06 2023-10-09 Method of treating medulloblastoma with an ezh2 inhibitor

Country Status (12)

Country Link
US (2) US20190083504A1 (enExample)
EP (2) EP4309738A3 (enExample)
JP (1) JP7045985B2 (enExample)
KR (1) KR20180058829A (enExample)
CN (1) CN108699046A (enExample)
AU (3) AU2016333982A1 (enExample)
CA (1) CA3000983A1 (enExample)
EA (1) EA201890878A1 (enExample)
IL (2) IL258510A (enExample)
MX (1) MX394355B (enExample)
SG (1) SG10201909413SA (enExample)
WO (1) WO2017062495A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190105669A (ko) 2012-10-15 2019-09-17 에피자임, 인코포레이티드 암을 치료하는 방법
WO2017035234A1 (en) 2015-08-24 2017-03-02 Epizyme, Inc. Method for treating cancer
US11951108B2 (en) 2016-01-29 2024-04-09 Epizyme, Inc. Combination therapy for treating cancer
US11786533B2 (en) 2016-06-01 2023-10-17 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
US11147819B2 (en) 2016-06-17 2021-10-19 Epizyme, Inc. EZH2 inhibitors for treating cancer
WO2018183885A1 (en) 2017-03-31 2018-10-04 Epizyme, Inc. Combination therapy for treating cancer
AU2018275123A1 (en) 2017-06-02 2020-01-30 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
WO2019018635A1 (en) 2017-07-19 2019-01-24 Children's Medical Center Corporation COMPOSITIONS AND METHODS FOR TREATING DISEASES ASSOCIATED WITH IMPRESSIVE FAULT
JP7399079B2 (ja) 2017-09-05 2023-12-15 エピザイム，インコーポレイティド 癌を処置するための併用療法
EP3976044A4 (en) * 2019-06-03 2024-08-07 Icahn School of Medicine at Mount Sinai Compounds and methods for inhibiting cancers via rest inhibition
CN111905102A (zh) * 2020-09-04 2020-11-10 福建医科大学附属第一医院 Ezh2抑制剂在治疗胶质瘤中的应用
KR102821233B1 (ko) 2022-02-10 2025-06-17 서울대학교병원 Hsp70을 표적으로 하는 수모세포종 치료 및 전이 억제 방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4236945A (en) * 1978-11-27 1980-12-02 Allegheny Ludlum Steel Corporation Phosphorus-iron powder and method of producing soft magnetic material therefrom
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US8846935B2 (en) * 2010-05-07 2014-09-30 Glaxosmithkline Llc Indazoles
MX2012012966A (es) 2010-05-07 2013-01-22 Glaxosmithkline Llc Indoles.
JO3363B1 (ar) * 2011-04-13 2019-03-13 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
US9085583B2 (en) 2012-02-10 2015-07-21 Constellation—Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
KR20190105669A (ko) * 2012-10-15 2019-09-17 에피자임, 인코포레이티드 암을 치료하는 방법
PL2953941T3 (pl) 2013-02-11 2017-11-30 Constellation Pharmaceuticals, Inc. Modulatory enzymów modyfikujących metyl, ich kompozycje i zastosowania
MX373187B (es) * 2013-12-06 2020-04-13 Epizyme Inc Terapia de combinación para tratar cáncer.
WO2017079757A1 (en) * 2015-11-06 2017-05-11 Epizyme, Inc. Pediatric dosing for treatment of cancer with an ezh2 inhibitor

Also Published As

Publication number Publication date
JP2018529742A (ja) 2018-10-11
CA3000983A1 (en) 2017-04-13
EP3371175A2 (en) 2018-09-12
IL258510A (en) 2018-05-31
KR20180058829A (ko) 2018-06-01
IL281318A (en) 2021-04-29
CN108699046A (zh) 2018-10-23
EA201890878A1 (ru) 2018-08-31
EP4309738A3 (en) 2024-07-17
SG10201909413SA (en) 2019-11-28
US20190083504A1 (en) 2019-03-21
JP7045985B2 (ja) 2022-04-01
WO2017062495A2 (en) 2017-04-13
WO2017062495A3 (en) 2017-06-08
AU2021204331A1 (en) 2021-07-22
MX394355B (es) 2025-03-24
MX2018004132A (es) 2018-09-26
AU2023246384A1 (en) 2023-11-02
EP4309738A2 (en) 2024-01-24
EP3371175A4 (en) 2019-09-25
US20200268765A1 (en) 2020-08-27

Similar Documents

Publication Publication Date Title
US20200268765A1 (en) Method of treating medulloblastoma with an ezh2 inhibitor
US12162865B2 (en) Methods of treating cancer
US20210008075A1 (en) Pediatric dosing for treatment of cancer with an ezh2 inhibitor
US20220193084A1 (en) Inhibitors of ezh2 and methods of use thereof
KR20180054793A (ko) 악성 간상소체 종양 또는 고칼슘혈증형 난소의 소세포 암을 치료하는 방법
EP3325488A1 (en) Chiral diaryl macrocycles and uses thereof
US20230201212A1 (en) Inhibitors of ezh2 and methods of use thereof
US20230404963A1 (en) Combinations of metap2 inhibitors and cd4/6 inhibitors for the treatment of cancer
US12161635B2 (en) Compositions and methods of treating PIK3CA helical domain mutant cancers

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted